First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis
Lists
Only you see this
Abstract
At a willingness-to-pay threshold of US$36 780/QALY, camrelizumab plus rivoceranib is likely to be a cost-effective option compared with sorafenib as first-line treatment for advanced hepatocellular carcinoma in China.
BibTeX
@inproceedings{xiang2024first,
author = {Guiyuan Xiang and Yue-Yue Huang and Ni Zhang and Xinyu Du and Yuanlin Wu and Lanlan Gan and Yanping Li and Tingting Jiang and Yao Liu},
title = {{First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis}},
booktitle = {Clinical},
year = {2024},
doi = {10.1177/11795549241299393},
}Loading related content...